110 related articles for article (PubMed ID: 28559943)
21. Dual time point FDG PET for evaluation of malignant pleural mesothelioma.
Yamamoto Y; Kameyama R; Togami T; Kimura N; Ishikawa S; Yamamoto Y; Nishiyama Y
Nucl Med Commun; 2009 Jan; 30(1):25-9. PubMed ID: 19306511
[TBL] [Abstract][Full Text] [Related]
22. Is FDG-PET/CT useful for managing malignant pleural mesothelioma?
Otsuka H; Terazawa K; Morita N; Otomi Y; Yamashita K; Nishitani H
J Med Invest; 2009 Feb; 56(1-2):16-20. PubMed ID: 19262009
[TBL] [Abstract][Full Text] [Related]
23. Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma.
Lopci E; Zucali PA; Ceresoli GL; Perrino M; Giordano L; Gianoncelli L; Lorenzi E; Gemelli M; Santoro A; Chiti A
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):667-75. PubMed ID: 25403555
[TBL] [Abstract][Full Text] [Related]
24. Preoperative evaluation of patients with malignant pleural mesothelioma: role of integrated CT-PET imaging.
Truong MT; Marom EM; Erasmus JJ
J Thorac Imaging; 2006 May; 21(2):146-53. PubMed ID: 16770231
[TBL] [Abstract][Full Text] [Related]
25. The Role of 18F-FDG PET/CT Integrated Imaging in Distinguishing Malignant from Benign Pleural Effusion.
Sun Y; Yu H; Ma J; Lu P
PLoS One; 2016; 11(8):e0161764. PubMed ID: 27560933
[TBL] [Abstract][Full Text] [Related]
26. The role of FDG PET-CT in differential diagnosis of pleural pathologies.
Elboga U; Yılmaz M; Uyar M; Zeki Çelen Y; Bakır K; Dikensoy O
Rev Esp Med Nucl Imagen Mol; 2012; 31(4):187-91. PubMed ID: 23067687
[TBL] [Abstract][Full Text] [Related]
27. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.
Ceresoli GL; Chiti A; Zucali PA; Rodari M; Lutman RF; Salamina S; Incarbone M; Alloisio M; Santoro A
J Clin Oncol; 2006 Oct; 24(28):4587-93. PubMed ID: 17008700
[TBL] [Abstract][Full Text] [Related]
28. [18-Fluoro-deoxy-glucose (15FDG) positon emission tomography (PET) for the evaluation of malignant pleural disease].
Meignan M; Paone G
Rev Pneumol Clin; 2006 Apr; 62(2):128-34. PubMed ID: 16670667
[TBL] [Abstract][Full Text] [Related]
29. Patterns of disease progression on 18F-fluorodeoxyglucose positron emission tomography-computed tomography in patients with malignant pleural mesothelioma undergoing multimodality therapy with pleurectomy/decortication.
Bille A; Chicklore S; Okiror L; Cook GJ; Spicer J; Landau D; Lang-Lazdunski L
Nucl Med Commun; 2013 Nov; 34(11):1075-83. PubMed ID: 23963351
[TBL] [Abstract][Full Text] [Related]
30. Integrated FDG PET-CT imaging improves staging in malignant pleural mesothelioma.
Krüger S; Pauls S; Mottaghy FM; Buck AK; Schelzig H; Hombach V; Reske SN
Nuklearmedizin; 2007; 46(6):239-43. PubMed ID: 18084678
[TBL] [Abstract][Full Text] [Related]
31. 18F-fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma.
Subramaniam RM; Wilcox B; Aubry MC; Jett J; Peller PJ
J Med Imaging Radiat Oncol; 2009 Apr; 53(2):160-9; quiz 170. PubMed ID: 19527361
[TBL] [Abstract][Full Text] [Related]
32. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
Yildirim H; Metintas M; Entok E; Ak G; Ak I; Dundar E; Erginel S
J Thorac Oncol; 2009 Dec; 4(12):1480-4. PubMed ID: 19875971
[TBL] [Abstract][Full Text] [Related]
33. Malignant Peritoneal Mesothelioma Masquerades as Peritoneal Metastasis on (18)F-FDG PET/CT Scans; a Rare Diagnosis that Should Not Be Missed.
Claimon A; Bang JI; Cheon GJ; Kim EE; Lee DS
Nucl Med Mol Imaging; 2015 Dec; 49(4):325-8. PubMed ID: 26550054
[TBL] [Abstract][Full Text] [Related]
34. Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma.
Veit-Haibach P; Schaefer NG; Steinert HC; Soyka JD; Seifert B; Stahel RA
Lung Cancer; 2010 Mar; 67(3):311-7. PubMed ID: 19482372
[TBL] [Abstract][Full Text] [Related]
35. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.
Francis RJ; Byrne MJ; van der Schaaf AA; Boucek JA; Nowak AK; Phillips M; Price R; Patrikeos AP; Musk AW; Millward MJ
J Nucl Med; 2007 Sep; 48(9):1449-58. PubMed ID: 17704250
[TBL] [Abstract][Full Text] [Related]
36. Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge.
Abbott DM; Bortolotto C; Benvenuti S; Lancia A; Filippi AR; Stella GM
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32392897
[TBL] [Abstract][Full Text] [Related]
37. Imaging in pleural mesothelioma: a review of imaging research presented at the 9th International Meeting of the International Mesothelioma Interest Group.
Nowak AK; Armato SG; Ceresoli GL; Yildirim H; Francis RJ
Lung Cancer; 2010 Oct; 70(1):1-6. PubMed ID: 20541834
[TBL] [Abstract][Full Text] [Related]
38. Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma.
Kaira K; Serizawa M; Koh Y; Takahashi T; Hanaoka H; Oriuchi N; Endo M; Kondo H; Nakajima T; Yamamoto N
Eur J Cancer; 2012 May; 48(8):1244-54. PubMed ID: 22330319
[TBL] [Abstract][Full Text] [Related]
39. 11. Evaluation of Patients with Known Mesothelioma with 18F-Fluorodeoxyglucose and PET. Comparison with Computed Tomography.
Zubeldia J; Abou-Zied M; Nabi H
Clin Positron Imaging; 2000 Jul; 3(4):165. PubMed ID: 11150768
[TBL] [Abstract][Full Text] [Related]
40. Computed tomography, positron emission tomography, positron emission tomography/computed tomography, and magnetic resonance imaging for staging of limited pleural mesothelioma: initial results.
Plathow C; Staab A; Schmaehl A; Aschoff P; Zuna I; Pfannenberg C; Peter SH; Eschmann S; Klopp M
Invest Radiol; 2008 Oct; 43(10):737-44. PubMed ID: 18791416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
